Literature DB >> 18204156

Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease.

R M Mroz1, A Holownia, E Chyczewska, E M Drost, J J Braszko, J Noparlik, K Donaldson, W Macnee.   

Abstract

cAMP responsive element binding protein (CREB) plays an important role in transcriptional machinery. CREB signaling is altered in patients with asthma. However, the role of CREB in chronic obstructive pulmonary disease (COPD) is less clear. In the present study we assessed changes in subcellular CREB distribution and activation (CREB-P) in 35 stable COPD patients treated with formoterol (F), formoterol+budesonide (F/ICS), and formoterol+budesonide+theophylline (F/ICS/Th) b.i.d. for 4 weeks, using SDS-PAGE/WB in cytosol and nuclear extracts of induced sputum cells. The expression of CREB was increased after F/ICS in both cytosolic and nuclear fractions by about 40% and 24%, respectively (P<0.001, P<0.01), while CREB-P increased after F/ICS by about 50% (P<0.01) in both compartments. These changes were not affected by theophylline. In F/ICS-treated patients, relative accumulation of CREB in cytosol was observed. These findings indicate, that poor response to ICS therapy may be related to increased CREB-associated signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18204156

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  8 in total

1.  Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers.

Authors:  Michael E Nicks; Maureen M O'Brien; Russell P Bowler
Journal:  COPD       Date:  2011-06-01       Impact factor: 2.409

2.  Cyclic AMP response element-binding protein prevents endothelial permeability increase through transcriptional controlling p190RhoGAP expression.

Authors:  Koteswara Rao Chava; Mohammad Tauseef; Tiffany Sharma; Dolly Mehta
Journal:  Blood       Date:  2011-11-02       Impact factor: 22.113

3.  The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD.

Authors:  Kirsty E Russell; Kian Fan Chung; Colin J Clarke; Andrew L Durham; Patrick Mallia; Joseph Footitt; Sebastian L Johnston; Peter J Barnes; Simon R Hall; Karen D Simpson; Malcolm R Starkey; Philip M Hansbro; Ian M Adcock; Coen H Wiegman
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

4.  Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy.

Authors:  A Holownia; R M Mroz; A Kolodziejczyk; E Chyczewska; J J Braszko
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

5.  Nuclear HSP90 and HSP70 in COPD patients treated with formoterol or formoterol and corticosteroids.

Authors:  A Holownia; R M Mroz; A Kielek; E Chyczewska; J J Braszko
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

6.  Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients.

Authors:  Adam Holownia; R M Mroz; T Skopinski; A Kielek; A Kolodziejczyk; E Chyczewska; J J Braszko
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

7.  Pulmonary microRNA profiles identify involvement of Creb1 and Sec14l3 in bronchial epithelial changes in allergic asthma.

Authors:  Sabine Bartel; Nikola Schulz; Francesca Alessandrini; Andrea C Schamberger; Philipp Pagel; Fabian J Theis; Katrin Milger; Elfriede Noessner; Stephen M Stick; Anthony Kicic; Oliver Eickelberg; Robert J Freishtat; Susanne Krauss-Etschmann
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

8.  The Risk G Allele of the Single-Nucleotide Polymorphism rs928413 Creates a CREB1-Binding Site That Activates IL33 Promoter in Lung Epithelial Cells.

Authors:  Alisa M Gorbacheva; Kirill V Korneev; Dmitry V Kuprash; Nikita A Mitkin
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.